KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Free Cash Flow (2016 - 2026)

Bristol Myers Squibb has reported Free Cash Flow over the past 18 years, most recently at $757.0 million for Q1 2026.

  • Quarterly Free Cash Flow fell 55.31% to $757.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.9 billion through Mar 2026, down 9.0% year-over-year, with the annual reading at $12.8 billion for FY2025, 7.87% down from the prior year.
  • Free Cash Flow was $757.0 million for Q1 2026 at Bristol Myers Squibb, down from $1.6 billion in the prior quarter.
  • Over five years, Free Cash Flow peaked at $6.0 billion in Q3 2025 and troughed at $757.0 million in Q1 2026.
  • The 5-year median for Free Cash Flow is $3.0 billion (2022), against an average of $3.1 billion.
  • The largest YoY upside for Free Cash Flow was 72.29% in 2025 against a maximum downside of 60.5% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $3.0 billion in 2022, then skyrocketed by 32.5% to $3.9 billion in 2023, then grew by 3.54% to $4.1 billion in 2024, then plummeted by 60.5% to $1.6 billion in 2025, then tumbled by 52.81% to $757.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Free Cash Flow are $757.0 million (Q1 2026), $1.6 billion (Q4 2025), and $6.0 billion (Q3 2025).